Clinical Outcomes of Stem Cell Therapy in Traumatology and Orthopedics

The Center for Advanced Cell Technologies ReoCell was represented at the scientific and practical conference ASIR 2026 “Current Challenges in the Treatment of Complications of Traumatic Injuries”, held on March 26–27 in Lviv.

More details about the conference

During the event, leading specialists of the ReoCell team presented advanced approaches to the application of cell-based technologies in traumatology and orthopedics, as well as clinical outcomes of patient treatment using mesenchymal stem cells (MSCs).

In particular, a scientific presentation was delivered by the Medical Director of ReoCell Clinic, orthopedic surgeon and traumatologist, PhD Dmytro Horban, titled: “Orthobiologics in Modern Surgical Practice” 

Relevance of Cell Therapy in Orthopedics

One of the key messages of the presentation highlighted that degenerative tissue changes are directly associated with chronic inflammation, which progresses with age and leads to a decline in function and quality of life.

Therefore, regenerative medicine is increasingly considered a promising therapeutic approach for degenerative joint disorders.

Role of Mesenchymal Stem Cells (MSCs)

The presentation emphasized that MSCs represent a key tool in regenerative medicine due to their ability to: 

• self-renew  

• secrete growth factors (VEGF, HGF, IGF-1) that promote tissue regeneration  

• exert immunomodulatory effects  

• differentiate into bone, cartilage, and adipose tissues  

Importantly, the primary therapeutic effect of MSCs is mediated not only through differentiation but predominantly via paracrine signaling and regulation of inflammation. 

Global Contextand Evidense Base

The presentation also outlined the global development of cell-based therapies: 

• over 1,500 clinical trials involving MSCs worldwide

• approximately 170,000 scientific publications

• broad application across multiple fields, including orthopedics, immunology, and inflammatory diseases

These data reflect the growing scientific and clinical interest in regenerative medicine and its integration into modern medical practice. 

ReoCell Clinical Experience

The presentation included clinical outcomes of patients treated at ReoCell Clinic using MSC-based therapy, demonstrating positive dynamics across key clinical parameters.

Pain Reduction (VAS)

At 6 months post-treatment: 

• mean pain score decreased from 8 to 2  

• in some patients, pain was reduced to complete resolution  

Functional Improvement (WOMAC)

Assessment using the WOMAC scale demonstrated significant functional improvement: 

• reduction from 80 to 20 points.

Functional Outcomes

Additional findings included: 

• increase in knee flexion range of motion by 10%  

• improvement in load-bearing function by 4% 

These findings indicate restoration of joint biomechanics. 

Outcomes in Nonunion Cases

Clinical outcomes for long bone nonunions included: 

• 71.4% — complete bone union  

• 28.6% — formation of stable callus  

These results demonstrate the potential of MSC therapy in complex clinical scenarios. 

Safety Profile

• 30% of patients experienced mild synovitis or discomfort  

• symptoms resolved spontaneously within 1–2 days  

• no pharmacological intervention was required  

Clinical Significanse

The obtained results suggest that MSC therapy, as part of a multimodal treatment approach, may: 

• reduce pain intensity  

• improve joint function  

• enhance mobility and quality of life  

• delay the need for surgical intervention  

Participation in ASIR 2026 confirms ReoCell’s active integration into the scientific and medical community of Ukraine. 

The presented data demonstrate that cell-based technologies are becoming an important tool in the management of orthopedic conditions, offering new opportunities for disease control and preservation of function.